Status:
TERMINATED
The Ideal Sequence of Hybrid Coronary Revascularization with Endoscopic Coronary Revascularization
Lead Sponsor:
Jessa Hospital
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-85 years
Phase:
NA
Brief Summary
Hybrid coronary revascularization (HCR), a combination of coronary artery bypass graft surgery (CABG) and percutaneous coronary intervention (PCI), has emerged as an alternative treatment for multives...
Detailed Description
Hybrid coronary revascularization (HCR) is an emerging approach for multivessel coronary artery disease (MVD) which combines the excellent long-term outcomes of surgery with the early recovery and red...
Eligibility Criteria
Inclusion
- Multivessel coronary disease, defined as ≥ 50% diameter stenosis by visual estimation in 2 or more of the three major epicardial vessels or major side branches, with at least one or more one stenosis amenable to revascularization with PCI, if the patient cannot be full revascularized by surgery for a specific reason as determined by the Heart Team. Patients with a non-dominant right coronary artery may be included if the left anterior descending artery (LAD) and left circumflex have ≥50% stenosis.
- Age 18-85
- Willing and able to provide informed, written consent
Exclusion
- Requirement for other cardiac or non-cardiac surgical procedures (e.g., valve replacement, carotid revascularization)
- Cardiogenic shock and/or need for mechanical/pharmacologic hemodynamic support at the time of randomisation
- Left main coronary artery disease
- Contraindication for dual antiplatelet therapy
- ST-Elevation Myocardial Infarction (STEMI)
- Previous cardiac surgery
- Participation in other interventional clinical trials
- Recent coronary intervention (PCI)
- Ongoing high risk non-ST-segment elevation acute coronary syndrome (ACS)
- Life expectancy \< 1 year
- Active bleeding more or equal to BARC 2 at time of randomisation
- Requiring renal replacement therapy
- Undergoing evaluation for organ transplantation
Key Trial Info
Start Date :
January 9 2023
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 9 2024
Estimated Enrollment :
4 Patients enrolled
Trial Details
Trial ID
NCT05184075
Start Date
January 9 2023
End Date
November 9 2024
Last Update
November 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jessa Hospital
Hasselt, Limburg, Belgium